The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Disease-associated Bias in T Helper Type 1 (Th1)/Th2 CD4+ T Cell Responses Against MAGE-6 in HLA-DRB10401+ Patients With Renal Cell Carcinoma or Melanoma
Open accessAbstract
T helper type 1 (Th1)-type CD4+ antitumor T cell help appears critical to the induction and maintenance of antitumor cytotoxic T lymphocyte (CTL) responses in vivo. In contrast, Th2- or Th3/Tr-type CD4+ T cell responses may subvert Th1-type cell-mediated immunity, providing a microenvironment conducive to disease progression. We have recently identified helper T cell epitopes derived from the MAGE-6 gene product; a tumor-associated antigen expressed by most melanomas and renal cell carcinomas. In this study, we have assessed whether peripheral blood CD4+ T cells from human histocompatibility leukocyte antigens (HLA)-DRβ1*0401+ patients are Th1- or Th2-biased to MAGE-6 epitopes using interferon (IFN)-γ and interleukin (IL)-5 enzyme-linked immunospot assays, respectively. Strikingly, the vast majority of patients with active disease were highly-skewed toward Th2-type responses against MAGE-6–derived epitopes, regardless of their stage (stage I versus IV) of disease, but retained Th1-type responses against Epstein-Barr virus– or influenza-derived epitopes. In marked contrast, normal donors and cancer patients with no current evidence of disease tended to exhibit either mixed Th1/Th2 or strongly Th1-polarized responses to MAGE-6 peptides, respectively. CD4+ T cell secretion of IL-10 and transforming growth factor (TGF)-β1 against MAGE-6 peptides was not observed, suggesting that specific Th3/Tr-type CD4+ subsets were not common events in these patients. Our data suggest that immunotherapeutic approaches will likely have to overcome or complement systemic Th2-dominated, tumor-reactive CD4+ T cell responses to provide optimal clinical benefit.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vaccination of melanoma patients with peptide- or tumorlysate-pulsed dendritic cells
Nestle, F. O., Alijagic, S., Gilliet, M., Sun, Y., Grabbe, S., Dummer, R., Burg, G., & Schadendorf, D. (1998) · Nature Medicine · doi:10.1038/nm0398-328 · Cited by 2,862 · cited 1×
“Th1-type CD4 T cells secreting IFN- appear crucial to the optimal generation and durability of specific CTL in vivo and may also serve to recruit these effector cells into the tumor microenvironment via delayed-type hypersensitivity responses (8).”
BackgroundDranoff, G., Jaffee, E., Lazenby, A., Golumbek, P., Levitsky, H., Brose, K., Jackson, V, Hamada, H., Pardoll, D., & Mulligan, R. C. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.8.3539 · Cited by 2,818
Reciprocal Control of T Helper Cell and Dendritic Cell Differentiation
Rissoan, M.-C., Soumelis, V., Kadowaki, N., Grouard, G., Briere, F., Malefyt, R. D. W., & Liu, Y.-J. (1999) · Science · doi:10.1126/science.283.5405.1183 · Cited by 1,846
INDUCTION OF TH1 AND TH2 CD4+T CELL RESPONSES:The Alternative Approaches
Constant, S. L., & Bottomly, K. (1997) · Annual Review of Immunology · doi:10.1146/annurev.immunol.15.1.297 · Cited by 1,459
The Central Role of CD4+ T Cells in the Antitumor Immune Response
Hung, K., Hayashi, R., Lafond-Walker, A., Lowenstein, C., Pardoll, D., & Levitsky, H. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.188.12.2357 · Cited by 1,345
Gorelik, L., & Flavell, R. A. (2001) · Nature Medicine · doi:10.1038/nm1001-1118 · Cited by 770
The role of CD4+ T cell responses in antitumor immunity
Pardoll, D. M., & Topalian, S. L. (1998) · Current Opinion in Immunology · doi:10.1016/s0952-7915(98)80228-8 · Cited by 672
Zou, W., Machelon, V., Coulomb-L'Hermin, A., Borvak, J., Nome, F., Isaeva, T., Wei, S., Krzysiek, R., Durand-Gasselin, I., Gordon, A., et al. (2001) · Nature Medicine · doi:10.1038/nm1201-1339 · Cited by 653
de Jong, E. C., Vieira, P. L., Kalinski, P., Schuitemaker, J. H. N., Tanaka, Y., Wierenga, E. A., Yazdanbakhsh, M., & Kapsenberg, M. L. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.168.4.1704 · Cited by 503
Distinct Role of Antigen-Specific T Helper Type 1 (Th1) and Th2 Cells in Tumor Eradication in Vivo
Nishimura, T., Iwakabe, K., Sekimoto, M., Ohmi, Y., Yahata, T., Nakui, M., Sato, T., Habu, S., Tashiro, H., Sato, M., et al. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.190.5.617 · Cited by 468
Zhang, X., Brunner, T., Carter, L., Dutton, R. W., Rogers, P., Bradley, L., Sato, T., Reed, J. C., Green, D., & Swain, S. L. (1997) · The Journal of Experimental Medicine · doi:10.1084/jem.185.10.1837 · Cited by 459
Jonuleit, H., Giesecke-Tuettenberg, A., T�ting, T., Thurner-Schuler, B., Stuge, T. B., Paragnik, L., Kandemir, A., Lee, P. P., Schuler, G., Knop, J., et al. (2001) · International Journal of Cancer · doi:10.1002/ijc.1323 · Cited by 375
Geiger, J. D., Hutchinson, R. J., Hohenkirk, L., McKenna, E. A., Yanik, G. A., Levine, J. E., Chang, A. E., Braun, T., & Mulé, J. J. (2001) · PubMed · Cited by 320
Identification of MAGE-3 Epitopes Presented by HLA-DR Molecules to CD4+ T Lymphocytes
Chaux, P., Vantomme, V., Stroobant, V., Thielemans, K., Corthals, J., Luiten, R., Eggermont, A. M. M., Boon, T., & van der Bruggen, P. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.189.5.767 · Cited by 234
Leen, A., Meij, P., Redchenko, I., Middeldorp, J., Bloemena, E., Rickinson, A., & Blake, N. (2001) · Journal of Virology · doi:10.1128/jvi.75.18.8649-8659.2001 · Cited by 230
Bellone, G., Turletti, A., Artusio, E., Mareschi, K., Carbone, A., Tibaudi, D., Robecchi, A., Emanuelli, G., & Rodeck, U. (1999) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65149-8 · Cited by 227
The critical role of Th1-dominant immunity in tumor immunology
Nishimura, T., Nakui, M., Sato, M., Iwakabe, K., Kitamura, H., Sekimoto, M., Ohta, A., Koda, T., & Nishimura, S. (2000) · Cancer Chemotherapy and Pharmacology · doi:10.1007/pl00014051 · Cited by 211
Seo, N., Hayakawa, S., Takigawa, M., & Tokura, Y. (2001) · Immunology · doi:10.1046/j.1365-2567.2001.01279.x · Cited by 206
In vivo priming of two distinct antitumor effector populations: the role of MHC class I expression.
Levitsky, H. I., Lazenby, A., Hayashi, R. J., & Pardoll, D. M. (1994) · The Journal of experimental medicine · doi:10.1084/jem.179.4.1215 · Cited by 189
Kobayashi, M., Kobayashi, H., Pollard, R. B., & Suzuki, F. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.160.12.5869 · Cited by 171
Zarour, H. M., Kirkwood, J. M., Kierstead, L. S., Herr, W., Brusić, V., Slingluff, C. L., Sidney, J., Sette, A., & Storkus, W. J. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.1.400 · Cited by 162
Self-citationHerr, W., Ranieri, E., Olson, W. C., Zarour, H. M., Gesualdo, L., & Storkus, W. J. (2000) · Blood · doi:10.1182/blood.v96.5.1857 · Cited by 153
Self-citationCytokine fields and the polarization of the immune response
Kourilsky, P. (2001) · Trends in Immunology · doi:10.1016/s1471-4906(01)02012-9 · Cited by 133
Swain, S. L., Mckonzie, D. T., Dutton, R. W., et al. (1988) · Immunological Reviews · doi:10.1111/j.1600-065x.1988.tb00742.x · Cited by 124
T Helper 1 Cytokine mRNA Is Increased in Spontaneously Regressing Primary Melanomas
Lowes, M. A., Bishop, G. A., Crotty, K. A., Barnetson, R. S. C., & Halliday, G. M. (1997) · Journal of Investigative Dermatology · doi:10.1111/1523-1747.ep12292705 · Cited by 122
MHC antigens in human melanomas.
Dj, R., Mattijssen, V., Broecker, E.-B., & Ferrone, S. (1991) · PubMed · Cited by 111
Fallarino, F., Grohmann, U., Bianchi, R., Vacca, C., Fioretti, M. C., & Puccetti, P. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.165.10.5495 · Cited by 93
Wittke, F., Hoffmann, R. F. G., Buer, J., Dallmann, I., Oevermann, K., Sel, S., Wandert, T., Ganser, A., & Atzpodien, J. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690189 · Cited by 89
Maeurer, M. J., Martin, D. M., Castelli, C., Elder, E. M., Leder, G. H., Storkus, W. J., & Lotze, M. T. (1995) · Cancer Immunology Immunotherapy · doi:10.1007/bf01527407 · Cited by 76
Self-citationNagai, H., Horikawa, T., Oka, M., Ichihashi, M., Hara, I., & Kamidono, S. (2000) · Journal of Investigative Dermatology · doi:10.1046/j.1523-1747.2000.00156.x · Cited by 67
Hoffmann, T. K., Meidenbauer, N., Müller‐Berghaus, J., Storkus, W. J., & Whiteside, T. L. (2001) · Journal of Immunotherapy · doi:10.1097/00002371-200103000-00011 · Cited by 60
Self-citationExpression of MAGE genes in osteosarcoma
Sudo, T., Kuramoto, T., Komiya, S., Inoue, A., & Itoh, K. (1997) · Journal of Orthopaedic Research® · doi:10.1002/jor.1100150119 · Cited by 57
The role of CD4+ tumor-infiltrating lymphocytes in human solid tumors
Goedegebuure, P. S., & Eberlein, T. J. (1995) · Immunologic Research · doi:10.1007/bf02918172 · Cited by 57
Melanoma vaccines: the paradox of T cell activation without clinical response
Nielsen, M.-B., & Marincola, F. M. (2000) · Cancer Chemotherapy and Pharmacology · doi:10.1007/pl00014052 · Cited by 45
Turvy, D. N., & Blum, J. S. (1998) · Journal of Immunological Methods · doi:10.1016/s0022-1759(97)00206-8 · Cited by 27
Oka, H., Emori, Y., Hayashi, Y., & Nomoto, K. (2000) · Cellular Immunology · doi:10.1006/cimm.2000.1715 · Cited by 16
Linnemann, T., Jung, G., & Walden, P. (2000) · Journal of Virology · doi:10.1128/jvi.74.18.8740-8743.2000 · Cited by 14
Cited by
Şenbabaoğlu, Y., Gejman, R. S., Winer, A. G., Liu, M., Van Allen, E. M., de Velasco, G., Miao, D., Ostrovnaya, I., Drill, E., Luna, A., et al. (2016) · Genome Biology · doi:10.1186/s13059-016-1092-z · Cited by 968
Ko, J. S., Zea, A. H., Rini, B. I., Ireland, J. L., Elson, P., Cohen, P., Golshayan, A., Rayman, P. A., Wood, L., Garcia, J., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1332 · Cited by 862
Self-citationDe Monte, L., Reni, M., Tassi, E., Clavenna, D., Papa, I., Recalde, H., Braga, M., Di Carlo, V., Doglioni, C., & Protti, M. P. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20101876 · Cited by 695
Cancer vaccines: between the idea and the reality
Finn, O. J. (2003) · Nature Reviews Immunology · doi:10.1038/nri1150 · Cited by 636
Prognostic Value of Tumor-Infiltrating CD4+ T-Cell Subpopulations in Head and Neck Cancers
Badoual, C., Hans, S., Rodriguez, J., Peyrard, S., Klein, C., Agueznay, N. E. H., Mosseri, V., Laccourreye, O., Bruneval, P., Fridman, W. H., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1886 · Cited by 598
Metadata
- Authors
- Tatsumi, T., Kierstead, L. S., Ranieri, E., Gesualdo, L., Schena, F. P., Finke, J. H., Bukowski, R. M., Mueller-Berghaus, J., Kirkwood, J. M., Kwok, W. W., & Storkus, W. J.
- Venue
- The Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2002-08-26
- Volume
- 196
- Issue
- 5
- Pages
- 619-628
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- OpenAlex
- W2119174775
- Cited by
- 314
- References
- 37
- FWCI
- 7.89
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.